Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Ohio

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational and Therapeutic Risk

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, the dissemination of knowledge about pharmaceutical interventions and their potential adverse effects has been a critical function. As the domain of mass production expands, particularly in the manufacturing and distribution of biologic therapies, the focus necessarily shifts from general health education to specific occupational and environmental exposures. One such area of concern involves the transition from broad health literacy to the targeted risk associated with exposure to therapeutic agents like Tysabri, a medication used in the management of certain chronic conditions. The occupational exposure concern arises primarily for workers involved in the production, handling, or administration of this drug, where the risk of developing Progressive Multifocal Leukoencephalopathy (PML) becomes a tangible hazard. This shift in perspective requires a careful examination of how general health principles apply to specific workplace settings, where the potential for exposure is not a matter of patient choice but of occupational necessity. The legacy of health information thus provides the groundwork for understanding the implications of such exposure, while the pivot to occupational concern demands a more focused inquiry into the legal and regulatory frameworks that govern worker safety and liability.

Medical Background and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised patients, and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri increases the risk of PML, and three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways and Clinical Presentation

The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JC virus to reactivate and cause PML. This immunosuppressive effect is compounded by prior use of other immunosuppressants, which further increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The duration of therapy is a key factor, with risk increasing beyond two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically presents with progressive neurological deficits, including cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. Early recognition is critical, as prompt discontinuation of Tysabri may improve outcomes, though many patients still experience severe disability or death (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Settlement Considerations

The boxed warning and prescribing information clearly state the PML risk and the need for monitoring. However, questions may arise about whether patients and healthcare providers were adequately informed about the magnitude of risk, particularly regarding the interaction of risk factors. The TOUCH program requires patients to read a Medication Guide and sign an enrollment form acknowledging risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients may argue that warnings were insufficient to convey the severity or likelihood of PML, especially in those with multiple risk factors. For Ohio patients who have developed PML after Tysabri use, potential legal claims may involve product liability, failure to warn, or negligence. The statute of limitations for personal injury claims in Ohio is generally two years from the date the injury was discovered or should have been discovered. Given the latency between Tysabri exposure and PML onset—which can range from months to years—the timeline for filing a claim is critical. Patients should consult with legal counsel promptly to assess their individual circumstances. Settlement considerations often include the severity of harm, medical expenses, lost income, and pain and suffering. Because PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), damages may be substantial. Evidence of inadequate warnings or failure to monitor could strengthen a claim. However, the existence of the boxed warning and TOUCH program may be used by the defense to argue that risks were adequately communicated.

Timeline Between Exposure and Documented Harm

The time from Tysabri initiation to PML diagnosis varies. Risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Some cases occur within months, while others develop after several years. This variability complicates the determination of when the injury was discovered for statute of limitations purposes. Ohio courts generally apply the discovery rule, meaning the clock starts when the patient knew or reasonably should have known of the injury and its cause. Tysabri-associated PML is a devastating condition with high morbidity and mortality. Ohio patients affected by this complication face complex medical and legal challenges. Understanding the risk factors, clinical presentation, and adequacy of warnings is essential. Given the two-year statute of limitations in Ohio, prompt legal consultation is advisable to preserve potential claims. The evidence underscores the importance of careful risk-benefit assessment before initiating Tysabri and vigilant monitoring during treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Ohio?

In Ohio, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For Tysabri-associated PML, the discovery rule applies, meaning the clock starts when the patient knew or reasonably should have known of the injury and its cause. Given the variable latency between Tysabri exposure and PML onset, prompt legal consultation is critical to preserve potential claims.

What are the main risk factors for developing PML while on Tysabri?

Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing Tysabri therapy.

How is PML diagnosed in Tysabri patients?

PML diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. Early recognition is critical, as prompt discontinuation of Tysabri may improve outcomes, though many patients still experience severe disability or death (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.